High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations

References

• Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4; PMID:12242449; http://dx.doi.org/10.1126/science.1076514
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
   Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311-9; PMID:25482239; http://dx.doi.org/10.1056/NEJMoa1411087
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015; 33:1430-7; PMID:25452452; http://dx.doi.org/10.1200/JCO.2014.59.0703
   Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373:123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A,Loriot Y et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387:1909-20; PMID:26952546; http://dx.doi.org/10.1016/S0140-6736(16)00561-4
   Google Scholar
• Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol 2016; advance online publication; PMID:27805626; http://dx.doi.org/10.1038/nrclinonc.2016.168
   Google Scholar
• Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol 2015; 51:221-8; PMID:25500094; http://dx.doi.org/10.1016/j.oraloncology.2014.11.014
   PubMed Web of Science ®Google Scholar
• Twa DDW, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, Slack GW, Gunawardana J, Lim RS, McPherson AW et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014; 123:2062-5; PMID:24497532; http://dx.doi.org/10.1182/blood-2013-10-535443
   PubMed Web of Science ®Google Scholar
• Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S et al. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature 2016; 534:402-6; PMID:27281199; http://dx.doi.org/10.1038/nature18294
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015; 14:847-56; PMID:25695955; http://dx.doi.org/10.1158/1535-7163.MCT-14-0983
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; http://dx.doi.org/10.11581078-0432.CCR-13-3271
   Google Scholar
• Roemer MGM, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ et al. PD-L1and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol 2016; 34:2690-7; PMID:27069084; http://dx.doi.org/10.1200/JCO.2016.66.4482
   Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:2509-20; PMID:26028255; http://dx.doi.org/10.1056/NEJMoa1500596
   PubMed Web of Science ®Google Scholar
• Lal N, Beggs AD, Willcox BE, Middleton GW. An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. Oncoimmunology 2015; 4(3):e976052; PMID:25949894; http://dx.doi.org/10.4161/2162402X.2014.976052
   Google Scholar
• Madore J, Strbenac D, Vilain R, Menzies AM, Yang JYH, Thompson JF, Long GV, Mann GJ, Scolyer RA, Wilmott JS. PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage III melanoma. Clin Cancer Res 2016; 22:3915-23; PMID:26960397; http://dx.doi.org/10.1158/1078-0432.CCR-15-1714
   Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348
   Google Scholar
• Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 2015; 1:1319-23; PMID:26181000; http://dx.doi.org/10.1001/jamaoncol.2015.2151
   PubMed Web of Science ®Google Scholar
• Mullane SA, Werner L, Rosenberg J, Signoretti S, Callea M, Choueiri TK, Freeman GJ, Bellmunt J. Correlation of Apobec Mrna expression with overall survival and pd-l1 pxpression in urothelial carcinoma. Sci Rep 2016; 6:27702; PMID:27283319; http://dx.doi.org/10.1038/srep27702
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale A-L et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415-21; PMID:23945592; http://dx.doi.org/10.1038/nature12477
   PubMed Web of Science ®Google Scholar
• Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013; 45:977-83; PMID:23852168; http://dx.doi.org/10.1038/ng.2701
   PubMed Web of Science ®Google Scholar
• Chen SH, Habib G, Yang CY, Gu ZW, Lee BR, Weng SA, Silberman SR, Cai SJ, Deslypere JP, Rosseneu M et al. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science 1987; 238:363-6; PMID:3659919; http://dx.doi.org/10.1126/science.3659919
   PubMed Web of Science ®Google Scholar
• Ramiro A, San-Martin BR, McBride K, Jankovic M, Barreto V, Nussenzweig A, Nussenzweig MC. The role of activation-induced deaminase in antibody diversification and chromosome translocations. Adv Immunol. 2007; 94:75-107; PMID:17560272; http://dx.doi.org/10.1016/S0065-2776(06)94003-6
   Google Scholar
• Cullen BR. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 2006; 80:1067-76; PMID:16414984; http://dx.doi.org/10.1128/JVI.80.3.1067-1076.2006
   Google Scholar
• Smith HC, Bennett RP, Kizilyer A, McDougall WM, Prohaska KM. Functions and regulation of the APOBEC family of proteins. Semin Cell Dev Biol 2012; 23:258-68; PMID:22001110; http://dx.doi.org/10.1016/j.semcdb.2011.10.004
   PubMed Web of Science ®Google Scholar
• McFadden D, others. Conditional logit analysis of qualitative choice behavior. 1973 [ cited 2016 Sep 3]; Available from: https://elsa.berkeley.edu/reprints/mcfadden/zarembka.pdf
   Google Scholar
• Koller D, Friedman N. Probabilistic Graphical Models: Principles and Techniques. Cambridge, MA: MIT Press; 2009.
   Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Argyris EG, Acheampong E, Wang F, Huang J, Chen K, Mukhtar M, Zhang H. The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology 2007; 367:440-51; PMID:17631933; http://dx.doi.org/10.1016/j.virol.2007.06.010
   PubMed Web of Science ®Google Scholar
• Hofmeyer KA, Jeon H, Zang X. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. J Biomed Biotechnol 2011; 2011:451694; PMID:21960736; http://dx.doi.org/10.1155/2011/451694
   PubMedGoogle Scholar
• Waeckerle-Men Y, Starke A, Wuthrich RP. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells. Nephrol Dial Transplant 2007; 22:1527-36; PMID:17339272; http://dx.doi.org/10.1093/ndt/gfl818
   Google Scholar
• Wang C-J, Chou F-C, Chu C-H, Wu J-C, Lin S-H, Chang D-M, Sytwu H-K. Protective role of programmed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models. Diabetes 2008; 57:1861-9; PMID:18420489; http://dx.doi.org/10.2337/db07-1260
   PubMed Web of Science ®Google Scholar
• Madsen P, Anant S, Rasmussen HH, Gromov P, Vorum H, Dumanski JP, Tommerup N, Collins JE, Wright CL, Dunham I et al. Psoriasis upregulated phorbolin-1 shares structural but not functional similarity to the mRNA-editing protein apobec-1. J Invest Dermatol 1999; 113:162-9; PMID:10469298; http://dx.doi.org/10.1046/j.1523-1747.1999.00682.x
   PubMed Web of Science ®Google Scholar
• Jang B-C, Park Y-K, Choi I-H, Kim S-P, Hwang J-B, Baek W-K, Suh M-H, Mun K-C, Suh S-I. 12-O-tetradecanoyl phorbol 13-acetate induces the expression of B7-DC, -H1, -H2, and -H3 in K562 cells. Int J Oncol 2007; 31:1439-47; PMID:17982670; http://dx.doi.org/10.3892/ijo.31.6.1439
   Google Scholar
• Emerit I, Cerutti PA. Tumour promoter phorbol-12-myristate-13-acetate induces chromosomal damage via indirect action. Nature 1981; 293:144-6; PMID:7266668; http://dx.doi.org/10.1038/293144a0
   PubMed Web of Science ®Google Scholar
• Andor N, Graham TA, Jansen M, Xia LC, Aktipis CA, Petritsch C, Ji HP, Maley CC. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med 2016; 22:105-13; PMID:26618723; http://dx.doi.org/10.1038/nm.3984
   PubMed Web of Science ®Google Scholar
• Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481:306-13; PMID:22258609; http://dx.doi.org/10.1038/nature10762
   PubMed Web of Science ®Google Scholar
• Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC Enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov 2015; 5:704-12; PMID:26091828; http://dx.doi.org/10.1158/2159-8290.CD-15-0344
   PubMed Web of Science ®Google Scholar
• Middlebrooks CD, Banday AR, Matsuda K, Udquim K-I, Onabajo OO, Paquin A, Figueroa JD, Zhu B, Koutros S, Kubo M et al. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat Genet 2016; 48:1330-8; PMID:27643540; http://dx.doi.org/10.1038/ng.3670
   PubMed Web of Science ®Google Scholar
• Briggs S, Tomlinson I. Germline and somatic polymerase ϵ and δ mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol 2013; 230:148-53; PMID:23447401; http://dx.doi.org/10.1002/path.4185
   PubMed Web of Science ®Google Scholar
• Khagi Y, Kurzrock R, Patel SP. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev 2016; pp 1-12; PMID:27873079; http://dx.doi.org/10.1007/s10555-016-9652-y
   Google Scholar
• Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214-8; PMID:23770567; http://dx.doi.org/10.1038/nature12213
   Google Scholar
• Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 2007; 104:20007-12; PMID:18077431; http://dx.doi.org/10.1073/pnas.0710052104
   PubMed Web of Science ®Google Scholar
• Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform 2011; 12:323; PMID:21816040; http://dx.doi.org/10.1186/1471-2105-12-323
   PubMed Web of Science ®Google Scholar
• Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013; 45:970-6; PMID:23852170; http://dx.doi.org/10.1038/ng.2702
   PubMed Web of Science ®Google Scholar
• Wang X. Firth logistic regression for rare variant association tests. Front Genet 2014; 5:187; PMID:24995013; http://dx.doi.org/10.3389/fgene.2014.00187
   Google Scholar
• Heinze G, Puhr R. Bias-reduced and separation-proof conditional logistic regression with small or sparse data sets. Stat Med 2010; 29:770-7; PMID:20213709; http://dx.doi.org/10.1002/sim.3794
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Harrell FE, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001; 54:774-81; PMID:11470385; http://dx.doi.org/10.1016/S0895-4356(01)00341-9
   PubMed Web of Science ®Google Scholar